ArticleBrain and behavior2025
Irisin/FNDC5 Regulates Endothelial Function to Improve Post-Stroke-Induced Cognitive Dysfunction by Stimulating AMPK-eNOS Signaling.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- FNDC5/irisin ameliorates diabetes-associated cognitive dysfunction via αVβ5-cAMP signaling to regulate oxidative stress, neuroinflammation and synaptic plasticity.Journal of translational medicine · 2026Article
- Efficacy of finerenone and/or roflumilast in alleviation of intestinal ischemic reperfusion injury via regulation of IL10/AMPK/VEGF/eNOS pathway in rats.Iranian journal of basic medical sciences · 2026Article
- Muscle-brain crosstalk in sarcopenia and cognitive impairment: endocrine signaling, metabolic regulation, and exercise modulation.Frontiers in endocrinology · 2026Review
- Irisin/FNDC5 Regulates Endothelial Function to Improve Post-Stroke-Induced Cognitive Dysfunction by Stimulating AMPK-eNOS Signaling.Brain and behavior · 2025Article
- Integrative neurobiological mechanisms of acupuncture in post-stroke cognitive impairment: from neurotransmission to brain network remodeling.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCognitive impairment is one of the main complications after a stroke and seriously affects the quality of life and survival time of patients, thereby causing a heavy burden on the social economy and public health. Although exercise is an effective non-pharmacological strategy for prevention and treatment of cognitive impairment, the mechanism(s) of this effect remain unclear.
methodsThe current study investigated the effects of irisin treatment on the behavioral characteristics of mice with post-stroke cognitive impairment (PSCI). The expression levels of platelet endothelial cell adhesion molecule 1 (PECAM, PECAM-1, CD31), glial fibrillary acidic protein (GFAP), vascular endothelial growth factor (VEGF), and molecules in the adenosine 5-monophosphate (AMP)-activated protein kinase (AMPK)-endothelial nitric oxide synthase (eNOS) signaling cascade in the hippocampus were then measured.
resultsIrisin significantly enhances learning and memory functions in cases of PSCI. This improvement correlates with a reduction in cerebral infarction size and decreased neuronal death. Additionally, irisin treatment resulted in a marked decrease in the levels of astrocytic scar formation in the cortex. Furthermore, irisin activates the AMPK-eNOS signaling pathway, which promotes the expression of VEGF. The irisin compounds are involved in the process of brain angiogenesis and play a critical role in endothelial and reactive astrocytes function.
conclusionThe study revealed a potential mechanism by which exercise-induced irisin secretion may attenuate PSCI. Irisin improved endothelial dysfunction and neuroinflammation, suggesting it may be a promising target for PSCI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.